Agilent Technologies, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Padraig McDonnell
- Full Time Employees
- 17,900
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 5301 Stevens Creek Boulevard Santa Clara CA United States of America 95051
- IPO Date
- Nov 18, 1999
- CIK
- 0001090872
- Website
- agilent.com
- Similar Companies
- Business
- Agilent Technologies, Inc. (NYSE: A) provides instruments, software, services, and consumables for the life sciences, diagnostics, chemical analysis, and applied markets. The company offers a broad portfolio of products and services including gas chromatography and liquid chromatography systems; mass spectrometry and molecular spectroscopy instruments; microarrays, automation, and informatics solutions; bioreagents, FISH probes, target enrichment, and next-generation sequencing tools; immunohistochemistry and pathology solutions; genomics, proteomics, and cell analysis platforms; sample preparation, GC and HPLC columns, spectrometry supplies, and consumables; as well as laboratory management services encompassing enterprise asset management, compliance support, training, and CrossLab virtual assist for remote technical support. Headquartered in Santa Clara, California, Agilent operates globally in more than 100 countries, serving analytical laboratories, pharmaceutical, biopharma, clinical diagnostics, environmental, forensics, food, energy, academia, and government sectors; it was spun off from Hewlett-Packard in 1999. Recent developments include the completion of its $925 million acquisition of BIOVECTRA, Inc., a Canada-based contract development and manufacturing organization specializing in biologics, active pharmaceutical ingredients, sterile fill-finish, plasmid DNA, mRNA, lipid nanoparticles, antibody-drug conjugates, and high-potency APIs, enhancing Agilent's CDMO capabilities for gene editing and therapeutics; a $7 million investment to modernize R&D and applications labs in Delaware; the launch of the Agilent Innovation Hub in partnership with the University of Melbourne; a strategic collaboration with SeqOne for liquid biopsy data analysis in oncology; and expansions such as a $725 million nucleic acid therapeutics facility in Frederick, Colorado, alongside new product launches driving growth in specialty CDMO services for siRNA and GLP-1 modalities.
BLCR: A Top Performing Active Large Cap ETF Worth Watching
SueWallSt Reminds Regencell Bioscience Holdings Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of June 23, 2026 - RGC
Lost Money on Lucid Group, Inc. (LCID)? Join Class Action Suit Seeking Recovery - Contact SueWallSt
RGC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Regencell Bioscience Holdings Securities Lawsuit - Contact Levi & Korsinsky
SRAD DEADLINE: Levi & Korsinsky Reminds Sportradar Group AG Investors of Upcoming Securities Class Action Deadline
VDY: A Canadian Yield Compounder, But Not My Top Pick Today
Oklo Strengthens Aurora-INL Path With DOE's PDSA Clearance
Lost Money on SES AI Corporation (SES)? Join Class Action Suit Seeking Recovery - Contact SueWallSt
Lost Money on POET Technologies Inc. (POET)? Join Class Action Suit Seeking Recovery - Contact SueWallSt
AVAV Shareholder Alert: AeroVironment, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 7, 2026 in BitGo Holdings, Inc. Lawsuit - BTGO
Lost Money on Zoetis Inc. (ZTS)? Join Class Action Suit Seeking Recovery - Contact SueWallSt
BMI Shareholder Alert: Badger Meter, Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
Agilent Technologies, Inc. (A) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation
Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma
Agilent (A) Reliance on International Sales: What Investors Need to Know
Agilent Q2 Earnings Call Shows Ignite Driving a Higher Outlook
Why Agilent Technologies Stock Triumphed on Thursday
Agilent, Unusual Machines, Best Buy And Other Big Stocks Moving Higher On Thursday